Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1984 2
1985 3
1986 4
1987 4
1988 24
1989 33
1990 8
1991 12
1992 21
1993 21
1994 21
1995 39
1996 21
1997 21
1998 30
1999 28
2000 20
2001 16
2002 15
2003 19
2004 21
2005 11
2006 14
2007 6
2008 8
2009 12
2010 7
2011 7
2012 5
2013 5
2014 3
2015 6
2016 10
2017 6
2018 5
2019 7
2020 6
2021 5
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

502 results

Results by year

Filters applied: . Clear all
Page 1
Rilmenidine: a clinical overview.
Reid JL. Reid JL. Am J Hypertens. 2000 Jun;13(6 Pt 2):106S-111S. doi: 10.1016/s0895-7061(00)00226-0. Am J Hypertens. 2000. PMID: 10921529 Review.
In the at-risk hypertensive, rilmenidine reduces left ventricular hypertrophy to a similar degree to other reference agents. New studies show a significant improvement in glucose metabolism in metabolic syndrome patients treated with rilmenidine, and a significant r …
In the at-risk hypertensive, rilmenidine reduces left ventricular hypertrophy to a similar degree to other reference agents. New stud …
Rilmenidine extends lifespan and healthspan in Caenorhabditis elegans via a nischarin I1-imidazoline receptor.
Bennett DF, Goyala A, Statzer C, Beckett CW, Tyshkovskiy A, Gladyshev VN, Ewald CY, de Magalhães JP. Bennett DF, et al. Aging Cell. 2023 Feb;22(2):e13774. doi: 10.1111/acel.13774. Epub 2023 Jan 20. Aging Cell. 2023. PMID: 36670049 Free PMC article.
The rilmenidine-induced longevity required the transcription factors FOXO/DAF-16 and NRF1,2,3/SKN-1. Furthermore, we find that autophagy, but not AMPK signaling, was needed for rilmenidine-induced longevity. Moreover, transcriptional changes similar to caloric restr …
The rilmenidine-induced longevity required the transcription factors FOXO/DAF-16 and NRF1,2,3/SKN-1. Furthermore, we find that autoph …
Rilmenidine: a novel antihypertensive agent.
Safar ME. Safar ME. Am J Med. 1989 Sep 18;87(3C):24S-29S. doi: 10.1016/0002-9343(89)90501-9. Am J Med. 1989. PMID: 2571292 Review.
Rilmenidine is a novel antihypertensive agent related to alpha 2-agonists. ...The dominant aspect of rilmenidine is the observed dissociation at therapeutic doses between antihypertensive and central effects. ...
Rilmenidine is a novel antihypertensive agent related to alpha 2-agonists. ...The dominant aspect of rilmenidine is the observ …
Update on rilmenidine: clinical benefits.
Reid JL. Reid JL. Am J Hypertens. 2001 Nov;14(11 Pt 2):322S-324S. doi: 10.1016/s0895-7061(01)02239-7. Am J Hypertens. 2001. PMID: 11721891 Review.
Rilmenidine is an imidazoline derivative that appears to lower blood pressure (BP) by an interaction with imidazoline (I1) receptors in the brainstem (and kidneys). Rilmenidine is as effective in monotherapy as all other first-line classes of drugs, including diuret …
Rilmenidine is an imidazoline derivative that appears to lower blood pressure (BP) by an interaction with imidazoline (I1) receptors …
Rilmenidine and vigilance. Review of clinical studies.
Mahieux F. Mahieux F. Am J Med. 1989 Sep 18;87(3C):67S-72S. doi: 10.1016/0002-9343(89)90509-3. Am J Med. 1989. PMID: 2571296 Review.
Analysis of these results illustrated that after short-term and repeated administration: (1) the effects on vigilance observed with rilmenidine 1 mg did not differ statistically from data observed with placebo; and (2) sedative effects observed with clonidine were signific …
Analysis of these results illustrated that after short-term and repeated administration: (1) the effects on vigilance observed with rilme …
Rilmenidine: a novel approach to first-line treatment of hypertension.
Laurent S, Safar M. Laurent S, et al. Am J Hypertens. 1992 Apr;5(4 Pt 2):99S-105S. doi: 10.1093/ajh/5.4.99s. Am J Hypertens. 1992. PMID: 1350733 Review.
Rilmenidine (RIL) is a novel antihypertensive drug selectively acting at the sites of imidazoline receptors. Compared with diuretics, beta-blockers, Ca2+ antagonists and angiotensin converting enzyme inhibitors, the four major groups recommended by the US Joint National Co …
Rilmenidine (RIL) is a novel antihypertensive drug selectively acting at the sites of imidazoline receptors. Compared with diuretics, …
Recent advances in the pharmacology of rilmenidine.
Montastruc JL, Macquin-Mavier I, Tran MA, Damase-Michel C, Koenig-Berard E, Valet P. Montastruc JL, et al. Am J Med. 1989 Sep 18;87(3C):14S-17S. doi: 10.1016/0002-9343(89)90499-3. Am J Med. 1989. PMID: 2571291 Review.
In conscious sino-aortic denervated dogs, rilmenidine (1 mg/kg orally for two weeks) significantly reduced blood pressure and heart rate. ...Rilmenidine also decreases catecholamine release from the adrenal medulla which might contribute to the antihypertensive effe …
In conscious sino-aortic denervated dogs, rilmenidine (1 mg/kg orally for two weeks) significantly reduced blood pressure and heart r …
Distinctive features of rilmenidine possibly related to its selectivity for imidazoline receptors.
Harron DW. Harron DW. Am J Hypertens. 1992 Apr;5(4 Pt 2):91S-98S. doi: 10.1093/ajh/5.4.91s. Am J Hypertens. 1992. PMID: 1350732 Review.
In isolated renal proximal tubule cells, where imidazoline binding has also been shown, rilmenidine inhibits reabsorption of sodium. Clinical studies comparing 1 mg rilmenidine with placebo demonstrated significant reductions in blood pressure (BP) (61% rilmenidi …
In isolated renal proximal tubule cells, where imidazoline binding has also been shown, rilmenidine inhibits reabsorption of sodium. …
Pharmacokinetics of rilmenidine.
Singlas E, Ehrhardt JD, Zech P, Pozet N, Genissel P. Singlas E, et al. Am J Cardiol. 1988 Feb 24;61(7):54D-59D. doi: 10.1016/0002-9149(88)90466-3. Am J Cardiol. 1988. PMID: 2894159
Rilmenidine, an alpha 2-adrenoceptor agonist, was studied (1 mg single dose) in order to determine the effects of pathology on its basic pharmacokinetic parameters. ...These relations allow the evaluation of the predicted steady-state level of rilmenidine for a give …
Rilmenidine, an alpha 2-adrenoceptor agonist, was studied (1 mg single dose) in order to determine the effects of pathology on its ba …
Pharmacokinetics of rilmenidine.
Genissel P, Bromet N. Genissel P, et al. Am J Med. 1989 Sep 18;87(3C):18S-23S. doi: 10.1016/0002-9343(89)90500-7. Am J Med. 1989. PMID: 2782323
Rilmenidine was not subjected to presystemic metabolism. Distribution was independent of the free fraction since rilmenidine was weakly bound to plasma proteins (less than 10 percent). ...In repeated administration, the linearity with dose of the pharmacokinetics of …
Rilmenidine was not subjected to presystemic metabolism. Distribution was independent of the free fraction since rilmenidine w …
502 results

Searches related to "rilmenidine"